Bio-Therapeutic Glycoproteins are bioactive compounds with carbohydrates attached to proteins. Glycan is the specific site where carbohydrate attaches to proteins and process of production is called glycosylation. Bio-therapeutic glycoproteins produced with glycan moieties that are similar to natural mammal glycans. The most common types are glycosylation O-linked and N-linked that are mainly depends on protein sequence attachment. Carbohydrates linked to proteins through either ? and ? linkages. Glycosylation is an important process of bio-therapeutic glycoproteins because it is critically modulated into bioactivity, stability, solubility against proteolysis, yield, clearance rate from circulation and immunogenicity. The bio-therapeutic glycoproteins mainly produced by yeast expression systems, insect cells, mammalian systems, and plant-based expression systems. In yeast expression systems, yeast is cultured chemically to scale up fermentation to an industrial level. Yeast and human share same N-glycan's linkage. Insect cells represent an alternative system for expression of recombinant bio-therapeutic proteins. Later recombinant proteins are separated from insect cells. Mammalian Systems are used to produce complex bio-therapeutic glycoproteins. Most of the FDA approved bio-therapeutic glycoproteins derived from mammalian systems. Plant-based expression systems used for the scale-up production of glycoproteins. Among all systems, mammalian systems are well established in pharmaceuticals. Some examples of bio-therapeutic glycoproteins include tocilizumab, bevacizumab, adalimumab, etc. The potential benefits of Bio-Therapeutic Glycoproteins have been a subject of rising industrial interest in the context of wide range application. So, far they include several protein classes like antisera, cytokines, clotting factors, hormones, enzymes and enzyme inhibitors have been best suited physiologically. The trend of industrial developments likely continues alongside with growing knowledge about the functions of bio-therapeutic glycoproteins. Bio-Therapeutic Glycoproteins are a fastest growing field in the pharmaceutical industry due to a wide range of applicability. The mammalian expression system is used to produce glycoproteins that coded with human-like glycans. Bio-Therapeutic glycoproteins represent an integrated treatment for most of the autoimmune disorders, cancers, replacement therapies like hormone and enzyme substituted. All these benefits of glycoproteins drive the robust growth of the Bio-Therapeutic Glycoproteins market. The global Bio-Therapeutic Glycoproteins market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Bio-Therapeutic Glycoproteins market based on company, product type, end user and key regions. This report studies the global market size of Bio-Therapeutic Glycoproteins in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Bio-Therapeutic Glycoproteins in these regions. This research report categorizes the global Bio-Therapeutic Glycoproteins market by top players/brands, region, type and end user. This report also studies the global Bio-Therapeutic Glycoproteins market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors. The following manufacturers are covered in this report, with sales, revenue, market share for each company: Genentech Hoffmann-La Roche Genzyme Corp Abbott Laboratories Amgen Biogen Merck GlaxoSmithKline Novartis Pharmaceuticals Corp Market size by Product Antisera Cytokines Clotting Factors Hormones Enzymes Enzyme Inhibitors Market size by End User Oncology and Haematology Diabetes Cardiology Inflammatory Diseases Others Market size by Region North America United States Canada Mexico Asia-Pacific China India Japan South Korea Australia Indonesia Singapore Malaysia Philippines Thailand Vietnam Europe Germany France UK Italy Spain Russia Central & South America Brazil Rest of Central & South America Middle East & Africa GCC Countries Turkey Egypt South Africa The study objectives of this report are: To study and analyze the global Bio-Therapeutic Glycoproteins market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025. To understand the structure of Bio-Therapeutic Glycoproteins market by identifying its various subsegments. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). Focuses on the key global Bio-Therapeutic Glycoproteins companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development. To project the value and sales volume of Bio-Therapeutic Glycoproteins submarkets, with respect to key regions. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. In this study, the years considered to estimate the market size of Bio-Therapeutic Glycoproteins are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025 This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Bio-Therapeutic Glycoproteins market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources. For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents 1 Study Coverage 1.1 Bio-Therapeutic Glycoproteins Product 1.2 Market Segments 1.3 Key Manufacturers Covered 1.4 Market by Type 1.4.1 Global Bio-Therapeutic Glycoproteins Market Size Growth Rate by Product 1.4.2 Antisera 1.4.3 Cytokines 1.4.4 Clotting Factors 1.4.5 Hormones 1.4.6 Enzymes 1.4.7
